Get the latest news on Pharmagen stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on PHRX performance

Latest Pharmagen Stock News | OTC:PHRX | Benzinga

Pharmagen Inc as a distributor of specialty drugs, compounding and admix pharmacy, and producer of over-the-counter branded multivitamins to the healthcare provider market. The company distributes hard-to-find and specialty drugs to the healthcare provider market throughout the United States, while functioning as an aggregator of real-time market demand for these products.

News

Intraday Update

Markets

Movers

Trading Ideas

ACLLF

AJINY

ANLKY

APCX

APYRF

ATAX

ATEYY

ATHHF

AUDC

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

BASI

BGMZF

CACI

CELG

CLCT

CLNFF

CTVEF

CWCO

DLTR

DRRX

DTEMF

DYFSF

ELAMF

ENTG

EPRT

EVOA

FNWB

FRMC

FTMNF

GGGOF

GRBK

HALL

HEMA

HLTOF

ICAD

ITEPF

JACK

LIBE

LINK

LOMLF

LTDH

LYTS

MCDMF

MDCO

MRRTY

NILSY

NTDOF

NUPMF

PCHM

PIFFY

PLMR

PRKA

RILY

RLBY

RPAY

Rwe Ag Ord Bearer Dm5 American Depository Receipt

RWEOY

SEGXF

SNDD

SQNXF

SUWN

SWKH

TERP

TGONF

TPVG

TRNO

TRXD

UEIC

UGDIF

VNCE

YDVL

ZEAL

GLTVF

Stocks That Hit 52-Week Highs On Tuesday

Pharmagen Inc

Loop Capital analyst Yun Kim maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Hold and lowers the price target from $330 to $300.

Price Target

Analyst Ratings

Loop Capital Maintains Hold on Salesforce, Lowers Price Target to $300

Loop Capital analyst Chris Dankert maintains Watsco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>) with a Hold and raises the price target from $450 to $460.

Loop Capital Maintains Hold on Watsco, Raises Price Target to $460

The&nbsp;Consumer Financial Protection Bureau (CFPB) has dismissed multiple lawsuits that had been put in place by the <a href="https://www.benzinga.com/personal-finance/25/02/43752458/russell-vought-orders-pause-on-all-cfpb-activity-critics-say-this-gives-corporations-the-green-light-to-scam-families">agency&#8217;s former director</a>.
What To Know: The CFPB on Thursday&nbsp;issued four notices of voluntary dismissal for cases involving Capital One Financial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>), Berkshire Hathaway Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) Vanderbilt Mortgage &amp; Finance, Rocket Companies Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) Rocket Homes Real Estate and loan servicer Pennsylvania Higher Education Assistance Agency, according to <a href="https://www.cnbc.com/2025/02/27/cfpb-drops-capital-one-rocket-mortgage-affiliate-lawsuits.html">CNBC</a>. 
The notices of voluntary dismissal were released in legal filings Thursday morning and come amid a shakeup at the agency sparked by Elon Musk&#8217;s Department of Government Efficiency, or DOGE.
The report indicates that DOGE&#8217;s government efficiency initiative has led to the closing of the CFPB&#8217;s headquarters in Washington, and the dismissal of around 200 agency employees.
Check This Out: <a href="https://www.benzinga.com/personal-finance/25/02/44009020/ron-paul-responds-to-elon-musks-doge-invite-id-love-to-help-bring-sanity-back-warns-of-big-threat-to-retirement-funds-and-401ks">Ron Paul Responds To Elon Musk&#8217;s DOGE Invite: &#8216;I&#8217;d Love to Help Bring Sanity Back!&#8217; — Warns Of Big &#8216;Threat&#8217; To Retirement Funds And 401(k)s</a>
The enforcement shift also aligns with a change in directors after Russell Vought took over for former director Rohit Chopra earlier this month. 
Under Chopra, the CFPB accused Capital One of withholding more than $2 billion in interest; argued that Vanderbilt ignored affordability signs; accused Rocket of providing illegal payments to real estate agents; and targeted the Pennsylvania Higher Education Assistance Agency&#8217;s loan collection process.
&#8220;The Plaintiff, the Consumer Financial Protection Bureau, dismisses with prejudice this action against all Defendants," the agency reportedly said in the Capital One case dismissal. 
CNBC reported that the agency used similar language in the other cases.
Shares of Capital One, Berkshire Hathaway and Rocket Companies all moved higher following the dismissals.
At the time of publication, <a href="http://pro.benzinga.com">Benzinga Pro</a> shows.
<ul>
<li><a href="http://benzinga.com/quote/cof">Capital One shares</a> up 1.34% at $199.41</li>
<li><a href="https://www.benzinga.com/quote/brk-b">Berkshire shares</a> up 2.06% at $504.30 and </li>
<li><a href="http://benzinga.com/quote/rkt">Rocket Companies</a> shares 0.34% at $13.13.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/44018084/trumps-tariffs-potential-stagflation-whats-driving-markets-thursday">Trump&#8217;s Tariffs, Potential &#8216;Stagflation&#8217;: What&#8217;s Driving Markets Thursday?</a></li>
</ul>
Photo: Shutterstock.

Government

Legal

Capital One, Berkshire Hathaway, Rocket Companies Shares Move Higher After CFPB Drops Lawsuits

Loop Capital analyst Jeffrey Stevenson maintains TopBuild (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) with a Buy and lowers the price target from $405 to $390.

Loop Capital Maintains Buy on TopBuild, Lowers Price Target to $390

Loop Capital analyst Laura Champine maintains Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) with a Hold and lowers the price target from $40 to $35.

SHOO

Loop Capital Maintains Hold on Steven Madden, Lowers Price Target to $35

Loop Capital analyst Alton Stump maintains Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) with a Hold and lowers the price target from $147 to $100.

CAVA

Loop Capital Maintains Hold on Cava Group, Lowers Price Target to $100

The Federal Reserve is expected to maintain its current interest rate policy for the foreseeable future, according to Cleveland Fed President Beth Hammack, as policymakers continue to evaluate inflation trends and labor market conditions. Hammack emphasized patience on Thursday, stating that while progress has been made, inflation is not yet on track to consistently meet the 2% target.
What Happened: The Federal Reserve, following its latest policy discussions, signaled that interest rates are likely to remain unchanged for an extended period. 
Hammack underscored that while the job market remains strong, inflation&#8217;s decline has been uneven, justifying a cautious approach before considering rate cuts, Reuters reports. &#8220;We have made good progress, but 2% inflation is not in sight just yet,&#8221; she said. The central bank&#8217;s benchmark rate currently stands between 4.25% and 4.5%.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/44015322/nvidia-analyst-sees-significant-upside-for-stock-with-favorable-riskreward">Nvidia Analyst Sees &#8216;Significant Upside&#8217; For Stock With Favorable Risk/Reward</a>
Hammack, who joined the Fed in August 2024, also suggested that monetary policy may already be near a neutral stance. &#8220;Policy does not strike me as being meaningfully restrictive; or, put differently, we may be close to a neutral setting already,&#8221; she noted.
While some policymakers believe inflation will gradually decline, she cautioned that economic uncertainties, including potential inflationary risks from trade and immigration policies, remain a concern, according to Reuters.
Why It Matters: The Fed&#8217;s stance on interest rates impacts borrowing costs, investment decisions, and overall economic stability. Despite the recent cooling of inflation, concerns remain about potential upward pressure stemming from geopolitical risks and policy shifts. 
According to the minutes from the Federal Open Market Committee's (FOMC) January meeting, officials remain divided on how quickly rate cuts should be implemented. Policymakers stress the need for more data before <a href="https://www.benzinga.com/25/02/43829352/fomc-minutes">making any adjustments.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/44015237/pending-home-sales-crash-to-record-low-jobless-claims-soar-wall-street-reacts">Pending Home Sales Crash To Record Low, Jobless Claims Soar: Wall Street Reacts</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Federal Reserve

Fed's Hammack: '2% Inflation Is Not In Sight'

Financial giants have made a conspicuous bullish move on Celsius Holdings. Our analysis of options history for Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) revealed 15 unusual trades.
Delving into the details, we found 53% of traders were bullish, while 46% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $105,280, and 12 were calls, valued at $875,865.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $33.33 for Celsius Holdings during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Celsius Holdings's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Celsius Holdings's whale trades within a strike price range from $15.0 to $33.33 in the last 30 days. 
<h3>Celsius Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740685588_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$15.85</td>
<td>$14.95</td>
<td>$14.95</td>
<td>$15.00</td>
<td>$224.2K</td>
<td>1.1K</td>
<td align="right">0</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$13.5</td>
<td>$12.25</td>
<td>$13.64</td>
<td>$20.00</td>
<td>$202.9K</td>
<td>668</td>
<td align="right">0</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.3</td>
<td>$3.2</td>
<td>$3.22</td>
<td>$27.50</td>
<td>$88.5K</td>
<td>1.3K</td>
<td align="right">313</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.15</td>
<td>$6.1</td>
<td>$6.15</td>
<td>$30.00</td>
<td>$60.8K</td>
<td>8.6K</td>
<td align="right">260</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$6.1</td>
<td>$6.05</td>
<td>$6.05</td>
<td>$30.00</td>
<td>$60.5K</td>
<td>8.6K</td>
<td align="right">360</td>
</tr>
</tbody>
</table>

<h3>About Celsius Holdings</h3>
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 96% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages, Celsius Essentials line (containing aminos), and Celsius On-the-Go powder packets. Celsius dedicates its efforts to branding and innovation, while it utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.
<h3>Present Market Standing of Celsius Holdings</h3>
<ul>
<li>With a trading volume of 4,480,233, the price of CELH is down by -2.66%, reaching $26.48.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 68 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Celsius Holdings</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $41.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Roth MKM lowers its rating to Buy with a new price target of $38. 
&#x2A; An analyst from Stifel persists with their Buy rating on Celsius Holdings, maintaining a target price of $37. 
&#x2A; An analyst from Needham persists with their Buy rating on Celsius Holdings, maintaining a target price of $40. 
&#x2A; An analyst from B. Riley Securities has revised its rating downward to Buy, adjusting the price target to $49. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Celsius Holdings options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

CELH

This Is What Whales Are Betting On Celsius Holdings

Investors with a lot of money to spend have taken a bullish stance on Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with CORT, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for Corcept Therapeutics.
This isn't normal.
The overall sentiment of these big-money traders is split between 80% bullish and 10%, bearish.
Out of all of the options we uncovered, 9 are puts, for a total amount of $812,152, and there was 1 call, for a total amount of $33,000.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $35.0 to $65.0 for Corcept Therapeutics over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Corcept Therapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Corcept Therapeutics's whale trades within a strike price range from $35.0 to $65.0 in the last 30 days. 
<h3>Corcept Therapeutics Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740685582_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$7.4</td>
<td>$6.6</td>
<td>$6.9</td>
<td>$65.00</td>
<td>$138.0K</td>
<td>1.1K</td>
<td align="right">500</td>
</tr>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.9</td>
<td>$8.3</td>
<td>$8.4</td>
<td>$65.00</td>
<td>$126.0K</td>
<td>1.1K</td>
<td align="right">800</td>
</tr>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$7.2</td>
<td>$5.6</td>
<td>$6.15</td>
<td>$65.00</td>
<td>$123.0K</td>
<td>1.1K</td>
<td align="right">250</td>
</tr>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.6</td>
<td>$7.5</td>
<td>$7.85</td>
<td>$65.00</td>
<td>$117.7K</td>
<td>1.1K</td>
<td align="right">650</td>
</tr>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.8</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$60.00</td>
<td>$101.0K</td>
<td>2.4K</td>
<td align="right">372</td>
</tr>
</tbody>
</table>

<h3>About Corcept Therapeutics</h3>
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
In light of the recent options history for Corcept Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Corcept Therapeutics's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 1,264,941, the CORT's price is down by -6.14%, now at $59.48. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 62 days.</li>
</ul>
<h3>Professional Analyst Ratings for Corcept Therapeutics</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $103.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from HC Wainwright &amp; Co. continues to hold a Buy rating for Corcept Therapeutics, targeting a price of $115. 
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Corcept Therapeutics, targeting a price of $130. 
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on Corcept Therapeutics, which currently sits at a price target of $78. 
&#x2A; Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $80. 
&#x2A; An analyst from HC Wainwright &amp; Co. has revised its rating downward to Buy, adjusting the price target to $115. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Corcept Therapeutics, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

CORT

Corcept Therapeutics's Options: A Look at What the Big Money is Thinking

Investors with a lot of money to spend have taken a bullish stance on United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with UPS, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 14 uncommon options trades for United Parcel Service.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 35%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $320,710, and 8 are calls, for a total amount of $340,863.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $105.0 and $130.0 for United Parcel Service, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for United Parcel Service's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of United Parcel Service's whale trades within a strike price range from $105.0 to $130.0 in the last 30 days. 
<h3>United Parcel Service Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740685577_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$1.59</td>
<td>$1.58</td>
<td>$1.59</td>
<td>$125.00</td>
<td>$86.1K</td>
<td>2.7K</td>
<td>855</td>
</tr>
<tr>
<td>UPS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$13.55</td>
<td>$13.35</td>
<td>$13.35</td>
<td>$125.00</td>
<td>$77.4K</td>
<td>0</td>
<td>58</td>
</tr>
<tr>
<td>UPS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$7.25</td>
<td>$7.1</td>
<td>$7.13</td>
<td>$105.00</td>
<td>$72.0K</td>
<td>32</td>
<td>101</td>
</tr>
<tr>
<td>UPS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/07/25</td>
<td>$1.78</td>
<td>$1.72</td>
<td>$1.78</td>
<td>$119.00</td>
<td>$69.0K</td>
<td>14</td>
<td>1.8K</td>
</tr>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.05</td>
<td>$5.85</td>
<td>$5.9</td>
<td>$120.00</td>
<td>$59.0K</td>
<td>2.6K</td>
<td>125</td>
</tr>
</tbody>
</table>

<h3>About United Parcel Service</h3>
As the world's largest parcel delivery company, UPS manages a massive fleet of more than 500 planes and 100,000 vehicles, along with many hundreds of sorting facilities, to deliver an average of about 22 million packages per day to residences and businesses across the globe. UPS' domestic US package operations generate around 65% of total revenue while international package makes up 20%. Air and ocean freight forwarding and contract logistics make up the remainder.
Following our analysis of the options activities associated with United Parcel Service, we pivot to a closer look at the company's own performance.
<h3>Where Is United Parcel Service Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 2,652,948, with UPS's price up by 1.35%, positioned at $118.47.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 54 days.</li>
</ul>
<h3>Expert Opinions on United Parcel Service</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $125.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Buy rating on United Parcel Service, which currently sits at a price target of $147. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Underweight rating on United Parcel Service, which currently sits at a price target of $82. 
&#x2A; In a cautious move, an analyst from Baird downgraded its rating to Neutral, setting a price target of $130. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Neutral rating on United Parcel Service with a target price of $120. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for United Parcel Service, targeting a price of $149. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for United Parcel Service, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Looking At United Parcel Service's Recent Unusual Options Activity

WIIM

CoreCivic shares are trading higher after a post on X suggested ICE expanded its detention network and all of the beds will be at privately-run ICE jails under deals with the company and GEO Group.

Lake Street analyst Ben Klieve upgrades MGP Ingredients (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGPI#NASDAQ">MGPI</a>) from Hold to Buy and lowers the price target from $55 to $45.

Upgrades

MGPI

Lake Street Upgrades MGP Ingredients to Buy, Lowers Price Target to $45

Maxim Group analyst Anthony Vendetti initiates coverage on Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) with a Buy rating and announces Price Target of $6.

Initiation

SSKN

Maxim Group Initiates Coverage On Strata Skin Sciences with Buy Rating, Announces Price Target of $6

Maxim Group analyst Tate Sullivan initiates coverage on Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) with a Buy rating and announces Price Target of $1.75.

SDST

Maxim Group Initiates Coverage On Stardust Power with Buy Rating, Announces Price Target of $1.75

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has applied for a transportation charter-party carrier permit in California, signaling its intent to enter the ride-hailing market, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-02-27/tesla-sets-sights-on-waymo-uber-in-california-ride-hailing-bid?srnd=homepage-americas&amp;sref=TBDibEcD">reports</a>. This move could provide a crucial new revenue stream as Tesla <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42777950/teslas-first-sales-drop-splits-wall-street-2025-will-be-the-prove-it-year">faces declining EV sales</a>, marking its first annual sales drop in over a decade. 
What To Know: While CEO Elon Musk has long envisioned a fully autonomous ride-hailing fleet, the application suggests Tesla will initially use human drivers, per Bloomberg. The permit Tesla is pursuing mirrors the one held by Waymo &#8211; Alphabet's robotaxi unit &#8211; but Tesla has yet to apply for a permit to operate fully autonomous vehicles in California.
Read Also: <a href="https://www.benzinga.com/general/market-summary/25/02/44018084/trumps-tariffs-potential-stagflation-whats-driving-markets-thursday">Trump&#8217;s Tariffs, Potential &#8216;Stagflation&#8217;: What&#8217;s Driving Markets Thursday?</a>
If approved, Tesla's entry into ride-hailing could directly challenge Uber, Lyft and Waymo. Musk has promised to <a href="https://www.benzinga.com/markets/equities/24/12/42575664/tesla-reportedly-in-talks-with-austin">launch the service in Austin by June</a> and expand to California by year-end, though specifics remain unclear. 
What Else: Tesla's push into ride-hailing aligns with Musk's broader focus on AI and robotics, particularly as regulatory and technological hurdles continue to delay full autonomy. 
Success in this space could help offset slowing car sales, but competition, regulatory challenges and the need for an effective ride-hailing infrastructure may complicate the rollout.
Read Next:<a href="https://www.benzinga.com/news/econ-s/25/02/43977811/mortgage-rates-drop-to-lowest-levels-since-december-but-housing-market-remains-largely-stuck" target="_blank" rel="noreferrer noopener"></a>
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/25/02/43977811/mortgage-rates-drop-to-lowest-levels-since-december-but-housing-market-remains-largely-stuck" target="_blank" rel="noreferrer noopener">Mortgage Rates Drop To Lowest Levels Since December, But Housing Market Remains ‘Largely Stuck' </a></li>
</ul>
Photo: Shutterstock

TSLA

Tesla Seeks California Ride-Hailing Permit Amid Declining EV Sales

Citigroup analyst Ronald Josey downgrades Ibotta (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NYSE">IBTA</a>) from Buy to Neutral and lowers the price target from $82 to $44.

Downgrades

IBTA

Citigroup Downgrades Ibotta to Neutral, Lowers Price Target to $44

Citigroup analyst Jon Tower maintains Sweetgreen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) with a Buy and lowers the price target from $43 to $39.

Citigroup Maintains Buy on Sweetgreen, Lowers Price Target to $39

On Thursday, NovoCure Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) reported a fourth-quarter loss of 61 cents, down from the 45-cent loss reported a year ago, missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss of 34 cents</a>.
Sales increased 21% year over year to $161.27 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b44002398/novocure-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-company-update" rel="noreferrer noopener">consensus of $157.81 million</a>.
<ul>
<li>The U.S., Germany, France and Japan contributed $107.2 million, $17.4 million, $15.7 million and $8.5 million in quarterly net revenues, respectively, with other active markets contributing $10.4 million.</li>
<li>Revenue in Greater China from Novocure's partnership with Zai Lab totaled $2.0 million.</li>
<li>Improved approval rates in the U.S. resulted in $8.3 million of increased net revenue from prior period claims during the quarter.</li>
</ul>
Annual sales reached $605 million, an increase of 19% year-over-year, primarily driven by continued launch success in France for Optune Gio, a wearable, portable, FDA-approved device indicated to treat a type of brain cancer in adult patients 22 years of age or older. Gross margin for the quarter was 79%.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42268730/novocures-recently-approved-tumor-treating-electric-fields-shows-promise-in-pancreatic-cancer-patients" rel="noreferrer noopener">NovoCure&#8217;s Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients</a>
As of December 31, 2024, there were 4,126 total active patients on TTFields therapy globally, with 4,077 active Optune Gio patients on therapy.
As of December 31, 2024, 20 active metastatic NSCLC patients and 29 active malignant pleural mesothelioma (MPM) patients were on Optune Lua, a wearable, portable, FDA-approved device used together with PD-1/PD-L1 inhibitors (immunotherapy) or docetaxel for adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41353867/fda-approves-novocures-portable-device-producing-tumor-treating-electric-fields-for-previously-tr" rel="noreferrer noopener">or after a platinum-based regimen</a>.
In 2025, Novocure expects gross margins will be impacted by current and future product enhancements, such as the U.S. launch of Head Flexible Electrode (HFE) transducer arrays for use with Optune Gio and the launch of Optune Lua in mNSCLC.
Net revenue growth in 2025 is expected to reflect growth in Optune Gio active patients. As the GBM business reaches maturity, the company expects to continue growing at a low, mid-single-digit rate this year.
Price Action: NVCR stock is down 10% at $19.77 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/44011524/dentsply-sirona-q4-earnings-miss-10-sales-drop-soft-2025-outlook-and-more" target="_blank" rel="noreferrer noopener">Dentsply Sirona Q4: Earnings Miss, 10% Sales Drop, Soft 2025 Outlook And More</a></li>
</ul>
Photo via Shutterstock.

Biotech

Earnings

Equities

Guidance

Health Care

General

NVCR

NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025

<a href="https://www.washingtonpost.com/technology/2025/02/27/tesla-robotaxi-california-elon-musk/" title="https://www.washingtonpost.com/technology/2025/02/27/tesla-robotaxi-california-elon-musk/">https://www.washingtonpost.com/technology/2025/02/27/tesla-robotaxi-california-elon-musk/</a>

Politics

GOOG

GOOGL

LYFT

UBER

'Elon Musk's Tesla moves to launch robotaxi service in California'

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/02/2025-02-27_09h55_19.png" alt="" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">Formidable Stage Five</h4>
Please <a href="https://thearorareport.com/chart-analysis-stock-market-nvidia-earnings-quantum-computing-breakthrough-nvda-mc-02272025">click here</a> for an enlarged chart of NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Note the following:
<ul>
<li>This article is about the big picture, not an individual stock.&nbsp; The chart of NVDA is being used to illustrate the point.</li>
<li>The chart shows NVDA stock moved up after the release of earnings.</li>
<li>Going into earnings, the whisper numbers for Nvidia were higher than the consensus. Nvidia earnings came inline with the whisper numbers.&nbsp; Stocks move based on the difference between whisper numbers and the reported numbers.&nbsp; Whisper numbers are the numbers analysts privately share with their best clients.&nbsp; Whisper numbers are often different consensus numbers that the same analysts publish for public consumption.</li>
<li>Initially, NVDA stock moved up on the headlines, but then it fell on concern about margins.&nbsp; In the overnight session, dip buyers came in and aggressively bought NVDA stock, running the stock back up.</li>
<li>The chart shows NVDA stock is now in the resistance zone.</li>
<li>The chart shows the move up was not on low volume.</li>
<li>In The Arora Report analysis, Nvidia earnings were excellent and the concern about margins is misplaced.&nbsp; Due to new product introduction, The Arora Report had expected lower margins.&nbsp; The reported margin is inline with our expectations.&nbsp;&nbsp;</li>
<li>In The Arora Report analysis, the most important point from Nvidia's conference call is that Nvidia has an aggressive new product map.  If Nvidia executes this product map, Nvidia will further distance itself from AMD and custom AI chip makers Broadcom Inc (AVGO) and Marvell Technology Inc (MRVL). </li>
<li>As we have shared with you before, the real issue facing NVDA as a stock is that it is in the formidable stage five of the stages of a long trade.&nbsp; Please <a href="https://thearorareport.com/ppp-long-trade-ppp">click here</a> to see the five stages.&nbsp;&nbsp;</li>
<li>As full disclosure, The Arora Report core position in NVDA with an average price of $12.55 was established when NVDA was in stage one.</li>
<li>The biggest losers from Nvidia earnings have been option players.&nbsp; Premiums on options were very expensive going into earnings as options were indicating a 10% move in NVDA stock after earnings. &nbsp; Since Nvidia has had a muted move after earnings, most of those expensive options are now worthless.</li>
<li>GDP is a lagging indicator, but nonetheless important because the market pays attention to it.&nbsp; The Arora Report focuses on leading indicators.&nbsp; Here are the details of the data:
<ul>
<li>Q4 GDP Second Estimate came at 2.3% vs. 2.3% consensus.</li>
<li>GDP Deflator Second Estimate came at 2.4% vs. 2.2% consensus.</li>
</ul>
</li>
<li>Initial jobless claims came at 242K vs. 220K consensus.&nbsp; In The Arora Report analysis, jobless claims are likely to rise further.&nbsp; Jobless claims is a leading indicator and carries heavy weight in the adaptive <a href="https://thearorareport.com/ALLOCATION%2BMODELS.htm">ZYX Asset Allocation Model</a> with inputs in ten categories.&nbsp; At The Arora Report, we are carefully watching the impact of DOGE on unemployment.&nbsp; So far, the data indicates only 614 former federal civilian employees applying for unemployment.&nbsp; However, prudent investors should note that the data has a two week delay.&nbsp;&nbsp;</li>
<li>Durable goods is mixed.&nbsp; Here are the details:
<ul>
<li>Durable goods came at 3.1% vs. 1.8% consensus.</li>
<li>Durable goods ex-transportation came at 0.0% vs. 0.4% consensus.</li>
</ul>
</li>
<li>Personal income, personal spending, and the Fed's favorite inflation gauge PCE will be released tomorrow at 8:30am ET.</li>
<li>After the recent leap in quantum computing by Microsoft Corp (MSFT), Amazon.com, Inc. (AMZN) has had its own breakthrough.  A team at California Institute of Technology has developed a new quantum computing chip Ocelot that can potentially reduce error correction cost by up to 90%. </li>
<li>In quantum computing, whisper numbers were very high compared to the consensus for IONQ Inc (IONQ).  IONQ reported inline with the consensus.  IONQ is also making a CEO transition, in addition to announcing a $500M at-the-market equity offering.</li>
</ul>
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Amazon (AMZN), Nvidia (NVDA), Alphabet Inc Class C (GOOG), Meta Platforms Inc (META), and Tesla Inc (TSLA).
In the early trade, money flows are negative in Apple Inc (AAPL).
In the early trade, money flows were positive in SPDR S&amp;P 500 ETF Trust (SPY) and Invesco QQQ Trust Series 1 (QQQ), but as of this writing in the premarket, they have turned negative.
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (GLD).  The most popular ETF for silver is iShares Silver Trust (SLV).  The most popular ETF for oil is United States Oil ETF (USO).
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin is range bound.
<h4 class="wp-block-heading">Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.&nbsp; The proprietary protection band from The Arora Report is very popular.&nbsp; The protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Market Summary

NVDA

Excellent Nvidia Earnings But Stage Five Pattern Proves Formidable, Quantum Computing Breakthrough

Pharmagen

Comments

Pharmagen Stock News

News

Latest Pharmagen Stock News | OTC:PHRX | Benzinga

Monday, September 23, 2019

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga